VIP: The Neuropeptide That Controls Your Immune System From Your Gut and Brain
Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide that acts as a powerful immune regulator, modulating inflammation and autoimmune responses through multiple immune cell types.
Quick Facts
What This Study Found
VIP (vasoactive intestinal peptide), a 28-amino-acid neuropeptide, functions far beyond its original discovery as a vasodilator. This review establishes VIP as a major immune regulator produced by both neurons and immune cells. VIP acts on macrophages, dendritic cells, and CD4+ T lymphocytes through specific receptors, modulating inflammatory and autoimmune responses.
The review covers VIP's involvement in inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, and other autoimmune conditions, as well as its current clinical applications and future therapeutic potential.
Key Numbers
28 amino acids · Expressed in CNS and peripheral nervous system · Acts on macrophages, dendritic cells, CD4+ T cells · Multiple receptor subtypes (VPAC1, VPAC2)
How They Did This
This is a comprehensive review of published literature on VIP's immune functions, covering VIP production by neurons and immune cells, receptor signaling pathways, effects on specific immune cell types (macrophages, dendritic cells, T lymphocytes), roles in inflammatory and autoimmune disorders, and current and potential therapeutic applications.
Why This Research Matters
VIP represents one of the clearest examples of how neuropeptides bridge the nervous and immune systems. Understanding VIP's immune functions opens therapeutic avenues for autoimmune diseases — conditions where the immune system attacks the body's own tissues. Unlike many immunosuppressants, VIP modulates rather than broadly suppresses immunity, potentially offering more targeted treatments with fewer side effects.
The Bigger Picture
VIP sits at the intersection of neuroscience and immunology — a field called neuroimmunology that is reshaping how we understand diseases from IBD to MS. As the therapeutic potential of immunomodulatory peptides gains attention (see also thymosin alpha-1, KPV), VIP represents one of the best-characterized examples of a neuropeptide with direct immune applications. The challenge remains delivering it effectively, as VIP is rapidly degraded in the body.
What This Study Doesn't Tell Us
As a review, this paper synthesizes existing knowledge rather than presenting new data. Much of the evidence for VIP's therapeutic potential comes from animal models of autoimmune disease. The translation of VIP-based therapies to human clinical use has been limited by the peptide's short half-life and delivery challenges.
Questions This Raises
- ?Can VIP analogs with extended half-lives be developed for practical clinical use in autoimmune diseases?
- ?How does VIP's immune modulation compare to other anti-inflammatory peptides like KPV or thymosin alpha-1?
- ?Could VIP-based therapies selectively treat autoimmune inflammation without compromising infection defense?
Trust & Context
- Key Stat:
- 28 amino acids VIP is a small neuropeptide with outsized immune effects — acting on macrophages, dendritic cells, and T cells to modulate inflammation
- Evidence Grade:
- This is a comprehensive review by established VIP researchers, published in a peer-reviewed journal. It synthesizes strong preclinical evidence across multiple disease models, but clinical human data on VIP-based therapies remains limited.
- Study Age:
- Published in 2013, this review provides a thorough foundation for understanding VIP's immune functions. While the basic science remains valid, more recent studies have advanced VIP analog development and clinical applications since this publication.
- Original Title:
- Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.
- Published In:
- Amino acids, 45(1), 25-39 (2013)
- Authors:
- Delgado, Mario(10), Ganea, Doina(4)
- Database ID:
- RPEP-02157
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does VIP do in the body?
VIP (vasoactive intestinal peptide) is a multitasking molecule. It widens blood vessels, stimulates secretions in the gut, acts as a neurotransmitter in the brain, and — as this review emphasizes — powerfully regulates immune responses by acting on macrophages, dendritic cells, and T cells to reduce inflammation.
Could VIP be used to treat autoimmune diseases?
In animal models of rheumatoid arthritis, IBD, and multiple sclerosis, VIP has shown strong anti-inflammatory and immunomodulatory effects. The main obstacle to clinical use is that VIP is rapidly broken down in the body, making effective delivery difficult. Researchers are working on longer-lasting VIP analogs and novel delivery methods.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02157APA
Delgado, Mario; Ganea, Doina. (2013). Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.. Amino acids, 45(1), 25-39. https://doi.org/10.1007/s00726-011-1184-8
MLA
Delgado, Mario, et al. "Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.." Amino acids, 2013. https://doi.org/10.1007/s00726-011-1184-8
RethinkPeptides
RethinkPeptides Research Database. "Vasoactive intestinal peptide: a neuropeptide with pleiotrop..." RPEP-02157. Retrieved from https://rethinkpeptides.com/research/delgado-2013-vasoactive-intestinal-peptide-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.